


# PRODUCT INFORMATION



## DL-3-Aminoisobutyric Acid (sodium salt)

Item No. 26537

**CAS Registry No.:** 84796-61-2  
**Formal Name:** 3-amino-2-methyl-propanoic acid, monosodium salt  
**Synonyms:** DL-β-Aminoisobutyric Acid, DL-BAIBA  
**MF:** C<sub>4</sub>H<sub>8</sub>NO<sub>2</sub> • Na  
**FW:** 125.1  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 204 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

DL-3-Aminoisobutyric acid (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the DL-3-aminoisobutyric acid (sodium salt) in the solvent of choice, which should be purged with an inert gas. DL-3-Aminoisobutyric acid (sodium salt) is soluble in the organic solvent DMSO at a concentration of approximately 10 mM.

### Description

DL-3-Aminoisobutyric acid is a non-proteinogenic amino acid formed during valine and thymine catabolism.<sup>1,2</sup> It decreases blood pressure in Dahl salt-sensitive rats fed a high-salt diet.<sup>3</sup> Saliva levels of DL-3-aminoisobutyric acid are increased in patients with head and neck cancer.<sup>4</sup>

### References

1. Roberts, L.D., Boström, P., O'Sullivan, J.F., *et al.* β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. *Cell Metab.* **19(1)**, 96-108 (2014).
2. van Kuilenburg, A.B., Meinsma, R., Beke, E., *et al.* β-Ureidopropionase deficiency: An inborn error of pyrimidine degradation associated with neurological abnormalities. *Hum. Mol. Genet.* **13(22)**, 2793-2801 (2004).
3. Cheng, Y., Song, H., Pan, X., *et al.* Urinary metabolites associated with blood pressure on a low- or high-sodium diet. *Theranostics* **8(6)**, 1468-1480 (2018).
4. Hynne, H., Sandås, E.M., Elgstøen, K.B.P., *et al.* Saliva metabolomics in dry mouth patients with head and neck cancer or Sjögren's syndrome. *Cells* **11(3)**, 323 (2022).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2025

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 • USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)